Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate to severe atopic dermatitis: results from the JADE REGIMEN phase 3 trial.

• Results Overview

  The study found that continuous treatment with abrocitinib helped prevent disease flares in patients who initially responded to treatment, and if flares occurred, restarting treatment was effective in regaining control of symptoms.

• Study Summary

  Num Participants:

  1,233

  Study Type:

  Rct

  Control Group:

  ['Abrocitinib 100 Mg', 'Placebo']

  Efficacy End Points Treatment:

  {'Flare probability': 18.9}

  Efficacy End Points Control:

  {'Flare probability': 80.9}

  Side Effects Treatment:

  Adverse Event	Severity	Percentage Affected

  Side Effects Control:

  Adverse Event	Severity	Percentage Affected